Immunological control of Pseudomonas infection in burn patients: a clinical evaluation.
D000293:Adolescent; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use; D000917:Antibody Formation; D001428:Bacterial Vaccines; D002056:Burns / Q000150:complications* / Q000188:drug therapy; D002648:Child; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007115:Immunization Schedule; D007271:Injections, Intradermal; D007273:Injections, Intramuscular; D008297:Male; D009504:Neutrophils / Q000276:immunology; D010587:Phagocytosis; D011552:Pseudomonas Infections / Q000517:prevention & control*; D011550:Pseudomonas aeruginosa; D013411:Sulfadiazine / Q000627:therapeutic use; D014611:Vaccination; D014946:Wound Infection / Q000517:prevention & control*
D000891:Anti-Infective Agents, Local; D001428:Bacterial Vaccines; D005839:Gentamicins; D013411:Sulfadiazine